Overview

A TQT Study of Effect of M2951 on Cardiac Repolarization

Status:
COMPLETED
Trial end date:
2023-08-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
Phase:
PHASE1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Treatments:
evobrutinib
Moxifloxacin